NervGen Pharma Corp. NGEN
—
1.94
(0.08)
(3.96%)
as of 25 Sep
- Market cap
- $217.2M
- P/E
- 0.0×
Follow NGEN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
1.23 | 1.34 | 1.16 | 0.79 |
+3 more quarters Free account |
Net Debt/EBITDA |
7.12 | 2.20 | 3.45 | 1.85 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | — | |
Operating CF/Net income |
0.19 | 4.89 | 0.23 | 1.29 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.02 | 0.02 | 0.03 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.04) | (0.07) | (0.06) | (0.05) | |
Cash per Share |
0.68 | 0.15 | 0.22 | 0.11 | |
Shareholders Equity per Share |
0.14 | 0.05 | 0.03 | (0.03) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.14 | 0.05 | 0.03 | (0.03) | |
Free Cash Flow |
(4.09) | (5.98) | (4.44) | (3.88) | |
Working Capital |
12.20 | 3.75 | 2.20 | (2.44) | |
Net Current Asset Value |
12.20 | 3.75 | 2.20 | (2.44) | |
| Other line items | |||||
Quick Ratio |
1.19 | 1.09 | 1.12 | 0.73 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.04) | (0.07) | (0.06) | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
0.11 | 0.15 | 0.18 | — | |
Average Payables |
3.44 | 3.71 | 3.47 | — | |
Average Assets |
38.69 | 13.08 | 15.42 | — | |
Average Common Equity |
5.91 | 2.50 | 2.18 | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates